{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:51:38Z","timestamp":1781196698537,"version":"3.54.1"},"reference-count":37,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CBM"],"published-print":{"date-parts":[[2020,10,28]]},"abstract":"<jats:p>BACKGROUND: Matrix metalloproteinase-9 (MMP-9) is an important mediator of invasion and metastasis in neoplasia. In thyroid cancer expression levels correlate with aggressiveness but data on peripheral MMP-9 levels are less definitive. OBJECTIVE: Prospective study evaluating serum MMP-9 in the diagnosis and prognosis of papillary thyroid cancer. METHODS: Serum samples of MMP-9 were drawn before surgery in 185 consecutively enrolled patients with nodular thyroid disease, stratified on pathology as benign disease (N= 88) and papillary thyroid cancer (N= 97). Serum MMP-9 was measured by an immunometric assay. RESULTS: MMP-9 levels were not different between benign vs malignant pathology (p= 0.3). In papillary thyroid cancer there was no significant difference in MMP-9 levels between histologies, TNM stage and invasive\/non-invasive cancers. High-risk patients with multiple features of aggressiveness had significantly higher MMP-9 levels compared to low-intermediate risk patients (767.5 \u00b1 269.2 ng\/ml vs 563.7 \u00b1 228.4 ng\/ml, p= 0.019). A cut-off of 806 ng\/ml distinguished high from low-intermediate risk patients with a sensitivity of 60% and a specificity of 87.36%, p= 0.018. In patients with available follow-up data (N= 78), MMP-9 was higher in patients who required \u2a7e 2 doses of 131I therapy (p= 0.009) and in those with biochemical evidence of persistent disease\/who required additional therapy to achieve disease-free status (p= 0.017). CONCLUSION: Serum MMP-9 is not useful in the diagnosis of PTC, but preliminary data shows that high pre-surgical serum MMP-9 levels may identify patients at higher risk of persistent disease who require intensive treatment. Large volume prospective studies are required to confirm this observation.<\/jats:p>","DOI":"10.3233\/cbm-190609","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T13:10:46Z","timestamp":1595337046000},"page":"337-346","source":"Crossref","is-referenced-by-count":5,"title":["Serum Matrix metalloproteinase-9 (MMP-9) can help identify patients with papillary thyroid cancer at high risk of persistent disease: Value and limitations of a potential marker of neoplasia"],"prefix":"10.1177","volume":"29","author":[{"given":"Ruxandra","family":"Dobrescu","sequence":"first","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, Bucharest, Romania"},{"name":"\u201cCI Parhon\u201d National Institute of Endocrinology, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Picu","sequence":"additional","affiliation":[{"name":"\u201cCI Parhon\u201d National Institute of Endocrinology, Bucharest, Romania"},{"name":"Faculty of Biology, University of Bucharest, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andra","family":"Caragheorgheopol","sequence":"additional","affiliation":[{"name":"\u201cCI Parhon\u201d National Institute of Endocrinology, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Manda","sequence":"additional","affiliation":[{"name":"\u201cCI Parhon\u201d National Institute of Endocrinology, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dumitru","family":"Ioachim","sequence":"additional","affiliation":[{"name":"\u201cCI Parhon\u201d National Institute of Endocrinology, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Goldstein","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, Bucharest, Romania"},{"name":"\u201cCI Parhon\u201d National Institute of Endocrinology, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corin","family":"Badiu","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, Bucharest, Romania"},{"name":"\u201cCI Parhon\u201d National Institute of Endocrinology, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/CBM-190609_ref1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jamaoto.2014.1","article-title":"Current thyroid cancer trends in the United States","volume":"140","author":"Davies","year":"2014","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.3233\/CBM-190609_ref2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1089\/thy.2016.0100","article-title":"Systematic review of trends in the incidence rates of thyroid cancer","volume":"26","author":"Wiltshire","year":"2016","journal-title":"Thyroid"},{"key":"10.3233\/CBM-190609_ref3","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3109\/10409238.2013.770819","article-title":"Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade","volume":"48","author":"Vandooren","year":"2013","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"10.3233\/CBM-190609_ref4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.mam.2011.10.015","article-title":"Human matrix metalloproteinases: An ubiquitarian class of enzymes involved in several pathological processes","volume":"33","author":"Sbardella","year":"2012","journal-title":"Mol Aspects Med"},{"key":"10.3233\/CBM-190609_ref5","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1186\/s12885-018-5112-0","article-title":"The role of matrix metalloproteinase-9 as a prognostic biomarker in papillary thyroid cancer","volume":"18","author":"Zarkesh","year":"2018","journal-title":"BMC Cancer"},{"key":"10.3233\/CBM-190609_ref6","first-page":"2308","article-title":"Immunohistochemical analysis of matrix metalloproteinase-9 predicts papillary thyroid carcinoma prognosis","volume":"17","author":"Liu","year":"2019","journal-title":"Oncol Lett"},{"key":"10.3233\/CBM-190609_ref7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s004280000286","article-title":"Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas","volume":"438","author":"Maeta","year":"2001","journal-title":"Virchows Arch"},{"key":"10.3233\/CBM-190609_ref8","doi-asserted-by":"crossref","first-page":"6670","DOI":"10.1038\/s41598-017-07118-7","article-title":"Values of ultrasound features and MMP-9 of papillary thyroid carcinoma in predicting cervical lymph node metastases","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci Rep"},{"key":"10.3233\/CBM-190609_ref9","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1158\/0008-5472.CAN-06-0739","article-title":"Conditional activation of RET\/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling","volume":"66","author":"Mesa","year":"2006","journal-title":"Cancer Res"},{"key":"10.3233\/CBM-190609_ref10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1677\/ERC-07-0212","article-title":"BRAF(V600E) mutation and the biology of papillary thyroid cancer","volume":"15","author":"Frasca","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"10.3233\/CBM-190609_ref11","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.clinbiochem.2011.04.019","article-title":"Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression","volume":"44","author":"Patel","year":"2011","journal-title":"Clin Biochem"},{"key":"10.3233\/CBM-190609_ref12","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.biochi.2005.01.014","article-title":"Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers","volume":"87","author":"Turpeenniemi-Hujanen","year":"2005","journal-title":"Biochimie"},{"key":"10.3233\/CBM-190609_ref13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0009-8981(01)00679-9","article-title":"Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood","volume":"314","author":"Jung","year":"2001","journal-title":"Clin Chim Acta"},{"key":"10.3233\/CBM-190609_ref14","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/1471-2407-9-390","article-title":"Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9\/NGAL in breast cancer disease","volume":"9","author":"Provatopoulou","year":"2009","journal-title":"BMC Cancer"},{"key":"10.3233\/CBM-190609_ref15","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/bjc.2012.93","article-title":"Serum matrix metalloproteinase 9 and colorectal neoplasia: a community-based evaluation of a potential diagnostic test","volume":"106","author":"Wilson","year":"2012","journal-title":"Br J Cancer"},{"key":"10.3233\/CBM-190609_ref16","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/sj.bjc.6603958","article-title":"Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients","volume":"97","author":"Hurst","year":"2007","journal-title":"Br J Cancer"},{"key":"10.3233\/CBM-190609_ref17","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1158\/1078-0432.CCR-06-2299","article-title":"Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution","volume":"13","author":"Wu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.3233\/CBM-190609_ref18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1089\/105072502760258622","article-title":"Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer","volume":"12","author":"Komorowski","year":"2002","journal-title":"Thyroid"},{"key":"10.3233\/CBM-190609_ref19","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3760\/cma.j.issn.0366-6999.20130172","article-title":"Correlations between papillary thyroid cancer and peripheral blood levels of matrix metalloproteinase-2, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and tissue inhibitor of metalloproteinase-2","volume":"126","author":"Zhou","year":"2013","journal-title":"Chin Med J (Engl)"},{"key":"10.3233\/CBM-190609_ref20","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1046\/j.1365-2265.2003.01749.x","article-title":"Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer","volume":"58","author":"Lin","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.3233\/CBM-190609_ref21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3950\/jibiinkoka.103.499","article-title":"Study of matrix metalloproteinase-2 and -9 in thyroid papillary cancer","volume":"103","author":"Maruyama","year":"2000","journal-title":"Nihon Jibiinkoka Gakkai Kaiho"},{"key":"10.3233\/CBM-190609_ref22","unstructured":"S.B. Edge, C.C. Compton, A.G. Fritz, F.L. Greene and A. Trotti, Thyroid cancer staging, in: AJCC Cancer Staging Manual, S.B. Edge, C.C. Compton, A.G. Fritz, F.L. Greene, A. Trotti, eds., Springer-Verlag, New York, 2010, pp. 59\u201364."},{"key":"10.3233\/CBM-190609_ref23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 american thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"10.3233\/CBM-190609_ref24","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1515\/CCLM.2007.283","article-title":"Matrix metalloprotease-2 and -9 concentration and activity in serum and culture medium samples: A methodological reappraisal","volume":"45","author":"Colotti","year":"2007","journal-title":"Clin Chem Lab Med"},{"key":"10.3233\/CBM-190609_ref25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc745","article-title":"New functions for the matrix metalloproteinases in cancer progression","volume":"2","author":"Egeblad","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.3233\/CBM-190609_ref26","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/0046-8177(92)90060-G","article-title":"Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue","volume":"23","author":"Campo","year":"1992","journal-title":"Hum Pathol"},{"key":"10.3233\/CBM-190609_ref27","doi-asserted-by":"crossref","unstructured":"S. Selemetjev, I. Doric, I. Paunovic, S. Tatic and D. Cvejic, Coexpressed high levels of VEGF-C and active MMP-9 are associated with lymphatic spreading and local invasiveness of papillary thyroid carcinoma, Am J Clin Pathol (2016).","DOI":"10.1093\/ajcp\/aqw184"},{"key":"10.3233\/CBM-190609_ref28","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3325\/cmj.2014.55.128","article-title":"Enhanced activation of matrix metalloproteinase-9 correlates with the degree of papillary thyroid carcinoma infiltration","volume":"55","author":"Marecko","year":"2014","journal-title":"Croat Med J"},{"key":"10.3233\/CBM-190609_ref29","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1089\/thy.2012.0043","article-title":"The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension","volume":"22","author":"Randolph","year":"2012","journal-title":"Thyroid"},{"key":"10.3233\/CBM-190609_ref30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/thy.2012.0567","article-title":"Impact of degree of extrathyroidal extension of disease on papillary thyroid cancer outcome","volume":"24","author":"Radowsky","year":"2014","journal-title":"Thyroid"},{"key":"10.3233\/CBM-190609_ref31","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1089\/thy.2017.0102","article-title":"Updated american joint committee on cancer\/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (Eighth Edition): What changed and why","volume":"27","author":"Tuttle","year":"2017","journal-title":"Thyroid"},{"key":"10.3233\/CBM-190609_ref32","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/bjc.2016.127","article-title":"Levels of matrix metalloproteinases differ in plasma and serum \u2013 aspects regarding analysis of biological markers in cancer","volume":"115","author":"Jonsson","year":"2016","journal-title":"Br J Cancer"},{"key":"10.3233\/CBM-190609_ref33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/117727190700200038","article-title":"The sample type usedaffects the levels of gelatinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in circulating blood of healthy controls and breast cancer patients","volume":"2","author":"Paula","year":"2007","journal-title":"Biomark Insights"},{"key":"10.3233\/CBM-190609_ref34","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ijc.22652","article-title":"Gelatinase concentrations and zymographic profiles in human breast cancer: matrix metalloproteinases circulating in plasma are better markers for the subclassification and early prediction of cancer: The coagulation\/fibrinolysis pathways alter the release, activation and recovery of different gelatinases in serum","volume":"121","author":"Mannello","year":"2007","journal-title":"Int J Cancer"},{"key":"10.3233\/CBM-190609_ref35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clinbiochem.2006.10.007","article-title":"Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma","volume":"40","author":"Gerlach","year":"2007","journal-title":"Clin Biochem"},{"key":"10.3233\/CBM-190609_ref36","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1515\/CCLM.2009.203","article-title":"Positive correlations between serum and plasma matrix metalloproteinase (MMP)-2 or MMP-9 levels in disease conditions","volume":"47","author":"Gerlach","year":"2009","journal-title":"Clin Chem Lab Med"},{"key":"10.3233\/CBM-190609_ref37","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/bjc.2013.49","article-title":"Assessing the value of matrix metalloproteinase 9 (MMP9) in improving the appropriateness of referrals for colorectal cancer","volume":"108","author":"Damery","year":"2013","journal-title":"Br J Cancer"}],"container-title":["Cancer Biomarkers"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/CBM-190609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:07:46Z","timestamp":1777385266000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/CBM-190609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,28]]},"references-count":37,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/cbm-190609","relation":{},"ISSN":["1875-8592","1574-0153"],"issn-type":[{"value":"1875-8592","type":"electronic"},{"value":"1574-0153","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,28]]}}}